Figure 1.
Kaplan-Meier analysis of overall survival in patients with ET (panel A, n=261) and PMF (panel B, n=87) according to the presence of different driver mutations. Patients qualified for triple-negative status if JAK2mut and CALRmut and MPLmut were all absent. For a subset of patients (ET: n=2, PMF: n=11) treated by hematopoietic stem cell transplantation, the follow-up was censored at the date of this intervention. In ET, univariate analyses resulted in an overall P value of 0.846 (A). In PMF, the same comparison gave a P value of 0.023 (B). Upon pairwise univariate comparisons, the CALRmut subgroup showed significantly better survival compared to JAK2mut (P=0.04) and triple-negative (P=0.01) PMF patients while JAK2mut patients showed only a tendency towards better overall survival compared to triple-negative patients (P=0.076). ET: essential thrombocythemia; PMF: primary myelofibrosis.